Journal
BLOOD
Volume 140, Issue 19, Pages 2076-2090Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022015677
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) /National Cancer Institute (NCI) [R01CA203965, R01CA260838]
- Department of Defense [W81XWH-18-10238]
- New Jersey Commission on Cancer Research [COCR22PRG004]
- NIH/NCI [R01CA227912, R01CA214746]
- NIH [R21AI128264]
- Flow Cytometry/Cell Sorting shared resource of Rutgers Cancer Institute of New Jersey [NIH/NCI P30CA072720]
Ask authors/readers for more resources
Recombinant LIF protein has been found to protect against tissue damage and mortality caused by GVHD without compromising graft-versus-leukemia activity. This protection is achieved by decreasing the infiltration and activation of immune cells and protecting intestinal stem cells through the activation of STAT1 signaling and downregulation of IL-12-p40 expression.
Graft-versus-host disease (GVHD) remains a major complication after allogeneic hematopoietic stem cell transplantation, a widely used therapy for hematologic malig-nancies and blood disorders. Here, we report an unexpected role of cytokine leukemia inhibitory factor (LIF) in protecting against GVHD development. Administrating recom-binant LIF protein (rLIF) protects mice from GVHD-induced tissue damage and lethality without compromising the graft-versus-leukemia activity, which is crucial to prevent tumor relapse. We found that rLIF decreases the infiltration and activation of donor immune cells and protects intestinal stem cells to ameliorate GVHD. Mechanistically, rLIF downregulates IL-12-p40 expression in recipient dendritic cells after irradiation through activating STAT1 signaling, which results in decreased major histocompatibility complex II levels on intestinal epithelial cells and decreased donor T-cell activation and infiltration. This study reveals a previously unidentified protective role of LIF for GVHD-induced tissue pathology and provides a potential effective therapeutic strategy to limit tissue pathology without compromising antileukemic efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available